Related Experiment Video
Updated: May 21, 2025
08:04
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.6K
PARP Inhibitors Rechallenge in Patients With Recurrent Ovarian Cancer: A Multicentre Real-World Study in China
Jin Li1,2, Lingjun Zhao3, Fei Zheng4
1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Summary
Poly (ADP-ribose) polymerase inhibitor (PARPi) rechallenge shows feasibility in recurrent ovarian cancer. Achieving complete response after chemotherapy and combination therapies may improve outcomes, suggesting a way to overcome PARPi resistance.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Recurrent ovarian cancer presents a significant clinical challenge, often necessitating novel therapeutic strategies.
- Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized ovarian cancer treatment, but resistance remains a hurdle.
- PARPi rechallenge is an emerging strategy for patients with recurrent disease.
Purpose of the Study:
- To evaluate the treatment patterns, outcomes, and safety of PARPi rechallenge in recurrent ovarian cancer.
- To identify patient populations who benefit most from PARPi rechallenge.
- To explore factors influencing progression-free survival (PFS) in this context.
Main Methods:
- A multicentre, retrospective, real-world study involving 70 patients with recurrent ovarian cancer across twelve hospitals in China.
- Data on demographics, clinical characteristics, and treatment were collected from electronic health records.
- Progression-free survival (PFS) following PARPi rechallenge (PARPi2) as maintenance therapy was the primary outcome.
Main Results:
- The median PFS for PARPi2 maintenance therapy was 8.6 months.
- Achieving complete response (CR) to prior chemotherapy significantly predicted longer PARPi2 use (OR=4.25, p=0.02).
- Combination therapies showed a trend towards longer PFS (11.0 months) compared to monotherapy (7.7 months); 2.9% discontinued PARPi2 due to adverse events.
Conclusions:
- PARPi rechallenge as maintenance therapy is feasible and generally well-tolerated in recurrent ovarian cancer.
- Complete response to last chemotherapy and combination therapies are associated with improved PFS, suggesting potential to overcome PARPi resistance.
